The margins improved in both business areas in line with our priorities and initiatives. The debt level continued to decrease, and we have achieved our ambition to lower the net debt in relation to EBITDA to below 3.0. AddLife is now ready to gradually increase acquisition activity, and at the beginning of April, the acquisition of Edge Medical was completed.
Investors
AddLife shares are traded on Nasdaq Stockholm, Nordic Large Cap
-
![Fredrik Dalborg Addlife Q1 2025]()
-
Significant improvements in all prioritised areas
ANNUAL REPORT 2024The companies within AddLife have done a fantastic job over the past year, achieving significant improvements in all priority areas. A focused effort to improve margins has yielded clear results. Our organic growth exceeds market growth, confirming our leading positions in rapidly growing market niches, our continuous development of the product portfolio, and our ability to gain market share.
![VD Ord Fredrik Dalborg Addlife]()
AddLife creates value
The laboratory and medical technology market is relatively insensitive to economic fluctuations. Growth tends to be stable and is mainly driven by population growth and an ageing population. These trends increase the demand for AddLife's healthcare and research products. Historically, the markets where we operate have grown at an annual rate of 2-4 percent.
AddLife’s subsidiaries are strongly cash generative, which gives financial opportunity for acquisitions and investments.
AddLife has substantial experience of acquisitions, identifying candidates and completing successful transactions.
AddLife’s subsidiaries have strong sales organisations with high technological expertise and long term customer relationships.
Target fulfilment 2024
Earnings growth
Profitability
Dividend
Contact us!
The investor pages contain all published financial information to facilitate investment decisions.
We are happy to assist you in understanding our business and financial results. Please do not hesitate to contact us if you would like more information, or if you have any suggestions for improving our service.
Contact: [email protected]
IR- and press contacts
Subscribe
Your subscription is now saved and you will receive an email to verify your email address and activate the subscription.